Gyre Therapeutics Inc (GYRE) Implied Volatility Current

Tracking GYRE implied volatility helps you identify when options premiums on Gyre Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Gyre Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when GYRE IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Gyre Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For GYRE, tracking metrics like GYRE IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on GYRE signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.

In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where GYRE implied volatility sits today versus where it has been. Our scanner ranks Gyre Therapeutics Inc implied volatility against its historical range, surfaces extremes in GYRE IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Gyre Therapeutics Inc IV is rich or cheap — measure it, then act on it.